CavtheRx

CavtheRx is a biotechnology company focused on developing caveolin modulators to treat vascular leakage and inflammatory diseases, particularly in the field of ophthalmology. The company's lead program, CVX-51401, is a synthetic peptide designed to inhibit caveolin-1, thereby reducing vascular permeability and inflammation in conditions such as wet age-related macular degeneration and uveitis. Founded based on research from Yale University, CavtheRx operated as a virtual company before its assets were transitioned to other entities like Trefoil Therapeutics. Its technology aims to provide a novel mechanism for managing edema and chronic inflammatory disorders by stabilizing the vasculature.